To assess 1-year recurrence-free survival (RFS) in patients with hepatocellular carcinoma (HCC) who are at high risk of Inguinal orchiectomy recurrence usingTACE combined with icaritin
The subjects voluntarily cooperated with the study and signed the informed consent,
Male or female, 18 years old ≤ age ≤75 years old,
The histopathologic diagnosis was hepatocellular carcinoma
R0 resection was performed within 4 to 8 weeks before recruitment (patients who were confirmed to have R0 resection by imaging and pathological examination were excluded from the study group if the residual R1, residual R2 or the margin of resection were not clear)
Known sarcomatoid hepatocellular carcinoma/mixed hepatocellular carcinoma-cholangiocarcinoma/fibrolamellar hepatocellular carcinoma;
A history of other malignancies in the past 5 years or at the same time;
Severe functional impairment of other important organs such as heart, brain, lung and kidney;
Patients with a history of immunodeficiency or autoimmune disease;
Single group
TACE combined with Acoradine
DrugTranscatheter hepatic arterial chemoembolization (TACE) : the treatment interval was 28 days, the window period was ± 7 days. Subjects received a maximum of 4 TACE treatments; reduced and delayed treatment: laboratory tests were performed before the start of each cycle of TACE, with investigator criteria confirming whether TACE treatment was feasible. Acoradine: 6 tablets bid, taken after meals for 6 months or until intolerable or progressive disease (starting one month after surgery) .
1 year recurrence-free survival rate ,1-year RFSR.
1 year recurrence-free survival rate ,1-year RFSR.
TTR( time to recurrence)
TTR( time to recurrence)
Click on the lead sponsor to view all of their trials.
